Bjarne Bogen (born 18 January 1951) is a Norwegian immunologist, inventor and physician. He is widely known for his research on DNA vaccines, autoimmune disorders and cancer immunology.
Bjarne Bogen | |
|---|---|
 Bjarne Bogen | |
| Born | Bjarne Bogen 18 January 1951 Oslo, Norway |
| Nationality | Norwegian |
| Occupation | Professor of immunology |
| Academic background | |
| Alma mater | University of Oslo |
| Academic work | |
| Institutions | University of Oslo, University of Tromsø, Norwegian School of Veterinary Science, Basel Institute for Immunology, Stanford University and Dana–Farber Cancer Institute |
| Main interests | Immunology, DNA vaccination |
Career
editBogen graduated with a medical degree from the University of Oslo in 1977. In the following two years, he completed his internship at Sandnessjøen Hospital and in Lurøy Municipality and Træna Municipality at the coastline of northern Norway.[1] In 1984, at the University of Tromsø he defended his PhD thesis entitled "Murine Th and B Lymphocyte Recognition of Isologous Immunoglobulin".
Since 1986, Bogen has been working at the Institute for Clinical Medicine at the University of Oslo, first as an associate professor before becoming full professor in 1993.[1] In 1991, he was authorized as a specialist in clinical immunology, and has since 1995 had a part-time position as a senior consultant at the Oslo University Hospital. He was director of the KG Jebsen Centre for Influenza Vaccine Research (JIV) from 2013 to 2019.
During his scientific career, Bogen has been a guest researcher at the Basel Institute for Immunology (1985–87), Stanford University (1996–97), Dana–Farber Cancer Institute (2004–05) and The Scripps Research Institute (2005, 2019–20).[2]
Bogen is a fellow of the Norwegian Academy of Science and Letters since 2007.[3] From 1997 to 2019, he was a member of the Editorial Board for Scandinavian Journal of Immunology and from 2005 to 2007 for the journal Hematologica. Throughout his career, he has supervised 27 PhD-students, along with 23 students enrolled in either MSc or MD-PhD student programs.
In 2018, Bogen became an honorary Member of the Norwegian Society for Immunology. In 2020 he was awarded the King Olav V Cancer Research Prize by the Norwegian Cancer Society for his work within cancer immunology and his contribution to development of personalized cancer vaccines (Vaccibody), as well as the Innovation Price of the University of Oslo for his research on DNA vaccines.
Research
editThroughout his career, Bogen has published more than 220 scientific papers, among them in scientific journals such as Cell, Immunity, Nature Biotechnology and Nature Communications.[4][5][6][7]
In the early 1990s, Bogen and co-workers discovered a new type of collaboration between T and B-cells (Idiotype-driven T-B collaboration)[8][4][9] and how such collaboration can, under unfortunate circumstances, lead to the development of autoimmune disorders[10] and B cell lymphomas.[11]
In another vein of research, Bogen et al. demonstrated that CD4 T-cells, in collaboration with macrophages, can kill cancer cells such as multiple myeloma cells in an antitumor immune response.[12][7][5][13] Bogen has received the Senior Research Award from the U.S. Multiple Myeloma Research Foundation (2002, 2004 and 2008).
In yet another direction of research, Bogen and co-workers have developed new types of vaccine molecules known as Troybodys[6] (Medinnova prize 1998) and Vaccibodies[14] (Medinnova prize 2003). Vaccibodies have been developed as preclinical DNA vaccines for infectious diseases such as influenza as well as for different types of cancers.[6][14][15] The biotech company Vaccibody AS was founded by Bogen and co-workers in 2007.
Teaching
editDuring the last 30 years, Bogen has given lectures for medical students and physicians in basic and clinical immunology. From 1998 to 2013, he was the Head of Studies of Immunology at the Faculty of Medicine, University of Oslo. In 2000, he published the textbook "Immunologi" (English: "Immunology") together with professor Ludvig A. Munthe,[16] for which they received the TanoAschehoug's-prize.
References
edit- ^ a b University of Oslo: Bjarne Bogen
- ^ Vaccibody company: Scientific Advisors [1] Archived 1 July 2019 at the Wayback Machine
- ^ "Medlemmer" (in Norwegian). Norwegian Academy of Science and Letters. Retrieved 12 August 2019.
- ^ a b Weiss S, Bogen B. (1991) MHC class II-restricted presentation of intracellular antigen. Cell. Feb 22;64(4):767-76. PMID 1847667
- ^ a b Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. (2011) Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.PMID 21407206
- ^ a b c Lunde E, Munthe LA, Vabø A, Sandlie I, Bogen B. (1999) Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol. Jul;17(7):670-5.PMID 10404160
- ^ a b Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity. Mar;22(3):371-83.PMID 15780993
- ^ Weiss S, Bogen B. (1989) B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci Jan;86(1):282-6. PMID 2492101
- ^ Munthe LA, Os A, Zangani M, Bogen B. (2004) MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol. Jun 15;172(12):7476-84. PMID 15187126
- ^ Munthe LA, Corthay A, Os A, Zangani M, Bogen B. (2005) Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol. Aug 15;175(4):2391-400. PMID 16081810
- ^ Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B. (2007) Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med. May 14;204(5):1181–91. Epub 2007 May 7. PMID 17485509
- ^ Lauritzsen GF, Weiss S, Dembic Z, Bogen B. (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A. Jun 7;91(12):5700-4.PMID 7911244
- ^ Dembic Z, Schenck K, Bogen B. (2000) Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A. Mar 14;97(6):2697-702. PMID 10706628
- ^ a b Fredriksen AB, Bogen B. (2007) Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood. Sep 15;110(6):1797-805. Epub 2007 May 31.PMID 17540847
- ^ Fredriksen AB, Sandlie I, Bogen B. (2006) DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther. Apr;13(4):776-85. Epub 2006 Jan 18.PMID 16414309
- ^ Universitetsforlaget: «Imunologi» [2][permanent dead link]